Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chiome Bioscience Inc.
  6. News
  7. Summary
    4583   JP3205350006

CHIOME BIOSCIENCE INC.

(4583)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Chiome Bioscience : Termination of Collaborative Development License and Exclusive Option Agreement for anti-Semaphorin 3A antibody

05/14/2021 | 11:47am EDT

May 14, 2021

Company: Chiome Bioscience Inc.

Representative: Shigeru Kobayashi, President & CEO

(Code: 4583, Tokyo Stock Exchange Mothers)

Inquiries: Arihiko Bijohira, Executive Director & CFO

Phone: +81-3-6383-3746

Termination of Collaborative Development License and Exclusive Option Agreement for

anti-Semaphorin 3A antibody

Chiome Bioscience announced that it has agreed with SemaThera Inc. to terminate the Collaborative Development License and Exclusive Option Agreement for anti-Semaphorin 3A antibody which was signed on 22 March 2018.

Both parties have been collaborating in the research of potential use of Semaphorin 3A inhibitors in diabetic macular edema under the exclusive agreement for 3 years. SemaThera will continue research and development of Sema 3A inhibitors in ophthalmology area and Chiome regains full rights to anti-Semaphorin 3A antibody for further development and licensing in all fields.

There is no impact on the financial performance in the fiscal period ending December 31, 2021.

Disclaimer

Chiome Bioscience Inc. published this content on 14 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 May 2021 15:46:09 UTC.


© Publicnow 2021
All news about CHIOME BIOSCIENCE INC.
08/13CHIOME BIOSCIENCE : Supplement Documents for Financial Results Q2 FY12/21
PU
08/13CHIOME BIOSCIENCE : Non-Consolidated Financial Results (Japanese GAAP) for the S..
PU
08/13Chiome Bioscience Inc. Reports Earnings Results for the Half Year Ended June ..
CI
05/14CHIOME BIOSCIENCE : Termination of Collaborative Development License and Exclusi..
PU
05/14CHIOME BIOSCIENCE : Non-Consolidated Financial Results (Japanese GAAP) for the T..
PU
05/14CHIOME BIOSCIENCE : Supplement Documents for Financial Results Q1 FY12/21
PU
05/14CHIOME BIOSCIENCE : Collaborative Research Agreement with Mologic Ltd. for antib..
PU
05/14Chiome Bioscience Inc. Announces Collaborative Research Agreement with Mologi..
CI
05/14Chiome Bioscience Inc. Announces Non-Consolidated Earnings Results for the Th..
CI
05/14Chiome Bioscience Inc. Announces Termination of Collaborative Development Lic..
CI
More news
Financials
Sales 2020 600 M 5,45 M 5,45 M
Net income 2020 -1 400 M -12,7 M -12,7 M
Net Debt 2020 - - -
P/E ratio 2020 -6,30x
Yield 2020 -
Capitalization 9 793 M 89,1 M 89,0 M
Capi. / Sales 2020 16,3x
Capi. / Sales 2021 13,4x
Nbr of Employees 53
Free-Float 94,2%
Chart CHIOME BIOSCIENCE INC.
Duration : Period :
Chiome Bioscience Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHIOME BIOSCIENCE INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 243,00 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Shigeru Kobayashi President & Representative Director
Akiyuki Furuya Independent Outside Director
Haruhisa Kubota Independent Outside Director
Arihiko Bijohira Director & Manager-Corporate Planning Office
Sector and Competitors
1st jan.Capi. (M$)
CHIOME BIOSCIENCE INC.30.65%89
MODERNA, INC.311.65%173 588
LONZA GROUP AG32.35%60 074
IQVIA HOLDINGS INC.43.07%49 116
CELLTRION, INC.-23.26%31 904
SEAGEN INC.-10.81%28 420